SLC5A2 and type 2 diabetes mellitus: If the renoprotective effect of tofogliflozin is also equivalent to that of other SGLT2 inhibitors, tofogliflozin will be a preferred option for patients with type 2 diabetes and renal impairment as tofogliflozin may preserve the patient’s QOL by reducing the frequency of nocturnal urination [15,16], which is frequently seen in patients with diabetes.